艾力斯：创新药品甲磺酸伏美替尼片和枸橼酸戈来雷塞片纳入医保

Core Viewpoint - The company announced that its innovative drugs, Fumetinib and Goleirese, have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, reflecting recognition of their clinical value and potential to reduce patient medication costs [1] Group 1 - Fumetinib is included for first-line and second-line treatment indications, with the agreement effective from January 1, 2026, to December 31, 2027 [1] - Goleirese is newly included for second-line treatment indications, with the same agreement period [1] - The inclusion of both drugs in the insurance list is expected to expand the beneficiary population, although sales promotion may face uncertainties due to market competition [1]